Top alert for 2014: MYGN (50%), LIVE (45%), CTIC (115%), KOOL (88%), PZG (32%), GOLD (6%), IOC (6%), RSOL(18%), PLUG (70%), IMMU (26%)

Tuesday, September 2, 2014

Premarket Trading Ideas for Sept 3rd: CNQR, WTSL, HELE, ISIS, GWRE, EFC, KTWO, WFT, TTPH, FLEX, NAV

Watchlist for Day trade: 
INFI, MBLY, DAL, JBLU, CNQR, WTSL, HELE , GWRE , WFT, NAV, TKMR, TOL, GIII , ISIS

Volatile Stock (Risky Stock): TASR, HGSH, DGLY, JRJC, ISNS, EFUT, KNDI, HPJ, VII

Russian Stock: RSX,RBL,RUSL,RUSS,YNDX,MBT,VIP

News that matter:

Concur said to be contemplating sale to software maker, Bloomberg says (CNQR)

The Wet Seal's Board of Directors voted to approve John D. Goodman’s Severance Agreement and Release with the Company (the “Severance Agreement”) (WTSL)

Helen of Troy lowers FY15 EPS ex-items view to $3.70-$3.80 from $4.30-$4.40, sees Q2 EPS ex-items 64c-69c, consensus 85c (HELE)

ISIS  Pharmaceutical licensing partner Antisense reprts ATL1103 phase 2 result, meets endpoint. (ISIS)
Capital Product Partners announces offering of 15 mln common units (CPLP)

Cleveland Biolabs to report outcome of July FDA meeting and host conference call at 11 am EST on September 3 (CBLI)

Ellington Financial commences public offering of 8 mln common shares representing limited liability company interests (EFC)

Guidewire Software beats by $0.09, beats on revs, sees Q1 71.5 M – 78.5M, vs 74.8 M expectation  but Fy15 guidance is below expectation (GWRE) 

K2M Group receives 510(k) clearance & CE Mark for MESA Hooks used in complex spine procedures (KTWO)

 Aviat Networks misses by $0.06, beats on revs; guides Q1 revs below consensus (AVNW) 

Endeavour Intl announces decision not to make interest payments of ~ $33.5 mln (END)

Baker Hughes closes previously announced acquisition of Weatherford's (WFT) pipeline and specialty services business (BHI) 

Flextronics received shareholder approval to purchase up to 20% of its outstanding shares; also, co's Board of Directors authorized management to purchase the co's shares in an aggregate amount of up to $500 mln (FLEX) 


Tetraphase Pharmaceuticals announces positive oral dosing data from lead-in of IGNITE 2 Phase 3 trial of eravacycline for the treatment of complicated urinary tract infections (TTPH)

No comments:

Post a Comment